Approved US PFIC drugs treat pruritus. The researcher behind a therapy targeting BSEP on diagnosis, data, and what comes next.
Opinion|Podcasts|July 31, 2024
Empowering Patients: Defining Moderate Plaque Psoriasis and the Promise of Novel Oral Systemic Treatments
Plaque psoriasis experts explore recent advancements in treatment options, patient experiences, and the potential of novel oral systemic therapies to reduce the burden of this prevalent chronic condition.
Advertisement
Advertisement
Related to this article
Florence Schleich, MD, PhD, explains how exacerbation phenotypes and useful biomarkers shift across anti-IL-5, anti-IL-5R, and anti-TSLP therapies.
Hematology in September 2026: ASH raises ferritin thresholds for iron deficiency, plus marstacimab in hemophilia and curative SCD care.
Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.
April Armstrong, MD, MPH, discusses 1-year RELIEVE-AD-PEDs data on rapid, sustained dupilumab disease control in adolescents with atopic dermatitis.
Physicians and patients cited perceived mild severity as the top reason for leaving HAE attacks untreated in a recent Adelphi survey.
Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.
Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.
Advertisement
Advertisement
Trending on HCPLive
1
Ritlecitinib Stabilizes Vitiligo in Tranquillo Trial, With Iltefat Hamzavi, MD
2
The Benefits and Limits of Enlicitide, With Ninel Hovnanians, MD
3
Advances in Treating High-Impact Psoriasis from EADV 2026
4
6 Nephrology Headlines You Missed in September 2026
5